Disease burden in Serbian patients with facioscapulohumeral muscular dystrophy

Branislav Ralic1, Noemi Albano2, Vanja Viric3

  • 1Department of Neurology, Clinical Hospital Center Zvezdara, Belgrade, Serbia.

Insights

The Serbian version of the FSHD-HI (FSHD-HI-RS) is a reliable and valid tool for measuring disease burden in facioscapulohumeral muscular dystrophy (FSHD) patients. This understandable and easy-to-use questionnaire captures disease-specific features effectively.

Area of Science:

  • Neurology
  • Rehabilitation Medicine
  • Quality of Life Research

Background:

  • Facioscapulohumeral muscular dystrophy (FSHD) poses a significant disease burden.
  • Existing generic quality of life (QoL) questionnaires may not capture disease-specific features of FSHD.
  • A validated disease-specific measure is needed for Serbian FSHD patients.

Purpose of the Study:

  • To adapt and validate the FSHD-Health Index (FSHD-HI) for Serbian patients with FSHD.
  • To establish the reliability and validity of the Serbian version of the FSHD-HI (FSHD-HI-RS) for measuring disease burden.

Main Methods:

  • Forty-one genetically confirmed FSHD1 patients participated.
  • Validation included reliability (internal consistency, test-retest) and validity (content, construct, criterion) analyses.
  • Patients completed the FSHD-HI-RS, Comprehensive Clinical Evaluation Form (CCEF), and Serbian SF-36 (Short Form Health Survey).

Main Results:

  • FSHD-HI-RS was found to be understandable, with appropriate and simple language.
  • Excellent internal consistency (Cronbach's alpha >0.90) and good test-retest reliability (ICC=0.91) were demonstrated.
  • Significant correlations were found between FSHD-HI-RS scores and disease duration, muscle strength (MRC sum score), CCEF, and SF-36 scores.

Conclusions:

  • The FSHD-HI-RS is an understandable, reliable, and valid instrument for assessing disease burden in Serbian FSHD patients.
  • The questionnaire is easy to administer and complete.
  • FSHD-HI-RS effectively captures disease-specific aspects of FSHD, complementing generic QoL measures.
Abstract

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.6K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
718
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K